Deflazacort NDC 81806-207

NDC codes

FDA NDC Directory

Product NDC (as listed)81806-207Labeler and product segments. Claims need a package NDC.

Product NDC at billing width81806-0207Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
81806-207-30	81806020730	1 BOTTLE in 1 CARTON (81806-207-30) / 30 TABLET in 1 BOTTLEMarketed from Jun 12, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deflazacort
Generic name (nonproprietary): deflazacort
Active ingredients: Deflazacort — 30 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Doppel Farmaceutici S.r.l.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219254
Marketing start: Jun 12, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 81806-207_5a099870-46c9-5d21-e063-6294a90a9a8fSPL ID 5a099870-46c9-5d21-e063-6294a90a9a8fSPL set ID 34a03eb7-74f5-4471-e063-6394a90aca63RxCUI 153098, 153880, 1870954, 1870958UNII KR5YZ6AE4B
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N481806020730 followed by a unit qualifier and the quantity

Package 81806-0207-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 27, 2026.

Indications (excerpt from the label)

Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Deflazacort tablets are a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)